Simply Wall St.
BillionToOne Leads 3 Value Stock Picks That May Offer Investment Opportunities
📈
AI Sentiment
Highly Positive
9/10
- Home
- BLLN
BLLN
BillionToOne Inc.
as of 02-09-2026 3:59pm EST
$92.70
+$2.09
+2.31%
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 3.9B | IPO Year: | 2025 |
| Target Price: | $137.83 | AVG Volume (30 days): | 222.9K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $80.00 - $138.70 | Next Earning Date: | 12-09-2025 |
| Revenue: | $254,136,000 | Revenue Growth: | 254.30% |
| Revenue Growth (this year): | 98.01% | Revenue Growth (next year): | 36.76% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -4038000.0 | FCF Growth: | N/A |
Latest BillionToOne Inc. News
BLLN Breaking Stock News: Dive into BLLN Ticker-Specific Updates for Smart Investing
Compare BLLN vs Leading Stocks
See how BLLN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BLLN BillionToOne Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.